| 2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2933.99.26 | 00 | Drugs: | | | | |
| 2933.99.42 | 00 | Acriflavine; Acriflavine hydrochloride; Carbadox; and Pyrazinamide | kg | Free | | 15.4￠/kg + 46% |
| 2933.99.51 | 00 | Cardiovascular drugs: | | | | |
| 2933.99.51 | 00 | Hydralazine hydrochloride | kg | Free | | 15.4￠/kg + 47.5% |
| 2933.99.55 | 20 | Tolmetin sodium dihydrate | kg | | | |
| 2933.99.55 | 30 | Tolmetin sodium (anhydrous) | kg | | | |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2933.99.58 | 00 | Droperidol; and Imipramine hydrochloride | kg | Free | | 15.4￠/kg + 45.5% |
| 2933.99.90 | 00 | Drugs | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2934.10.70 | 00 | 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one; Ethyl 2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetate; Ethyl 2-(2-aminothiazol-4-yl)-2- methoxyiminoacetate; 2-Methyl-4-isothiazolin- 3-one; 2-n-Octyl-4-isothiazolin-3-one; and Thiothiamine hydrochloride | kg | Free | | 30.5% |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.20.30 | 00 | 2-Amino-6-methoxybenzothiazole; 2-Amino-6-methylbenzothiazole; 6-Ethoxy-2-benzothiazolethiol; 3-Methylbenzothiazole-2-hydrazone; and Primuline base | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30.23 | 00 | Drugs: | | | | |
| 2934.99.05 | 00 | 5-Amino-3-phenyl-1,2,4-thiadiazole (3-Phenyl-5-amino-1,2,4-thiadiazole); 2-Hydroxybenzoxazole (Benzoxazolone); 4-Phenylmorpholine; 1,9-Thianthrenedicarboxylic acid; and Thioxanthene-9-one (Thioxanthone) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.99.30 | 00 | Drugs | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4￠/kg + 45% |
| 2934.99.47 | 00 | Drugs | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2934.99.70 | 00 | Morpholinoethyl chloride hydrochloride; 2-Methyl-2,5-dioxo-1-oxa-2-phospholan; and (6R-trans)-7-Amino-3-methyl-8-oxo-5- thia-1-azabicyclo[4.2.0]-oct-2-ene-2- carboxylic acid | kg | Free | | 30.5% |
| 2935.00.10 | 00 | 2-Amino-N-ethylbenzenesulfonanilide; 5-Amino- α, α, α-trifluorotoluene-2,4-disulfonamide; Benzenesulfonamide; Benzenesulfonyl hydrazide; 2-Chloro-4-amino-5-hydroxybenzenesulfonamide; 2,5-Dimethoxysulfanilanilide; and Metanilamide | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4￠/kg + 41% |
| 2935.00.29 | 00 | Drugs: | | | | |
| 2937.21.00 | | Cortisone, hydrocortisone, prednisone (dehydrocortisone), and prednisolone (dehydrohydrocortisone) | | Free | | 25% |
| 2937.21.00 | 20 | Hydrocortisone | g | | | |
| 2937.22.00 | 00 | Halogenated derivatives of adrenal cortical hormones | g | Free | | 25% |
